학술논문
323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S686-S686
Subject
Language
ISSN
0923-7534